Views: 1,458 | Downloads:
23
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Somatostatin Receptor Tumor Imaging (Tc 99m P829) in Pituitary Adenoma
Chiewvit S 
,
Chiewvit P ,
Pusuwan P ,
Sriussadaporn S ,
Ratanamart V
,
Chiewvit P ,
Pusuwan P ,
Sriussadaporn S ,
Ratanamart V Technetium 99mP829 (99mTc P829) is a somatostatin like structure labelled with Technetium-
99m. Somatostatin receptor positive tumors such as pituitary tumors, neuroendocrine
tumors, and lymphomas show positive scintigraphy. Eleven patients suspected of having a pituitary
mass (12 studies) were studied with 99mTc P829. Three pituitary adenoma patients (4 studies)
showed positive somatostatin receptor tumor imaging. Eight negative somatostatin receptor
scintigraphy were one hypothyroid induced pituitary hyperplasia, one craniopharyngioma, one
normal pituitary tissue with focal hyperplasia, one ACTH secreting pituitary tumor, one GH, PRL
secreting pituitary tumor post transphenoidal partial tumor removal, and no surgery in 3 patients.
Finally, somatostatin receptor imaging may be useful as a tumor localizing technique in addition
to conventional CT and MRI imaging and identify patients who might potentially benefit from
octreotide treatment. In addition, the development of peptide analogs coupling to B-emitting
radiopharmaceutical may lead to a situation in which diagnosis peptide receptor scintigraphy can
be followed by radionuclide therapy.
Key word : Somatostatin Receptor Tumor, Imaging, Pituitary Adenoma, Tc 99m P829
99m. Somatostatin receptor positive tumors such as pituitary tumors, neuroendocrine
tumors, and lymphomas show positive scintigraphy. Eleven patients suspected of having a pituitary
mass (12 studies) were studied with 99mTc P829. Three pituitary adenoma patients (4 studies)
showed positive somatostatin receptor tumor imaging. Eight negative somatostatin receptor
scintigraphy were one hypothyroid induced pituitary hyperplasia, one craniopharyngioma, one
normal pituitary tissue with focal hyperplasia, one ACTH secreting pituitary tumor, one GH, PRL
secreting pituitary tumor post transphenoidal partial tumor removal, and no surgery in 3 patients.
Finally, somatostatin receptor imaging may be useful as a tumor localizing technique in addition
to conventional CT and MRI imaging and identify patients who might potentially benefit from
octreotide treatment. In addition, the development of peptide analogs coupling to B-emitting
radiopharmaceutical may lead to a situation in which diagnosis peptide receptor scintigraphy can
be followed by radionuclide therapy.
Key word : Somatostatin Receptor Tumor, Imaging, Pituitary Adenoma, Tc 99m P829
Download:
PDF